2023 World Conference on Lung Cancer (Posters)-P1.25. Surgical Outcomes in Patients with Resected Node-negative Lung Adenocarcinoma of 2 cm or Smaller

P1.25. Surgical Outcomes in Patients with Resected Node-negative Lung Adenocarcinoma of 2 cm or Smaller - PDF(Abstract)

Pdf Summary

This study investigated the prognostic factors in patients with node-negative lung adenocarcinoma of 2 cm or smaller. The study included 599 patients who underwent surgical resection at Taipei Veterans General Hospital from 2006 to 2018. The recurrence rate was 6.3%, and the factors associated with a higher risk of recurrence were older age, larger tumor size, and a histological subtype of micropapillary/solid predominant pattern. The extent of pulmonary resection (wedge resection vs. anatomical resection) did not have a significant impact on the probability of freedom from recurrence (FFR).<br /><br />The study found that patients with lepidic-predominant adenocarcinoma had a 5-year probability of FFR of 97.5%. However, patients with the micropapillary/solid predominant pattern had a significantly lower probability of FFR. These findings suggest that patients with node-negative lung adenocarcinoma of 2 cm or smaller have a good prognosis after surgical resection, but those with older age, larger tumor size, and the micropapillary/solid predominant pattern are at a higher risk of recurrence.<br /><br />The information obtained from this study could be useful in identifying potential candidates for adjuvant therapy. Adjuvant therapy may be considered for patients with the identified risk factors to improve their outcomes. Overall, this study highlights the importance of considering various prognostic factors in order to tailor treatment strategies for early-stage non-small cell lung cancer patients.

Asset Subtitle

Jung-Jyh Hung

Meta Tag

Speaker Jung-Jyh Hung

Topic Early-Stage NSCLC: Changing Paradigms & Outcomes

Keywords

prognostic factors

node-negative lung adenocarcinoma

2 cm or smaller

surgical resection

recurrence rate

older age

larger tumor size

micropapillary/solid predominant pattern

adjuvant therapy

early-stage non-small cell lung cancer